Literature DB >> 28626730

Albumin-Bilirubin Grade and Hepatocellular Carcinoma Treatment Algorithm.

Masatoshi Kudo.   

Abstract

Entities:  

Year:  2017        PMID： 28626730      PMCID： PMC5473061          DOI： 10.1159/000462199

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  27 in total

1.  Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy.

Authors:  H Lau; K Man; S T Fan; W C Yu; C M Lo; J Wong
Journal:  Br J Surg       Date:  1997-09       Impact factor: 6.939

2.  Comparison of the grade evaluated by "Liver damage" of Liver Cancer Study Group of Japan and Child-Pugh classification in patients with hepatocellular carcinoma.

Authors:  Katsuhisa Omagari; Kazuo Ohba; Yoshiko Kadokawa; Hiroaki Hazama; Jun-Ichi Masuda; Hideki Kinoshita; Isao Matsuo; Ken Ohnita; Yohei Mizuta; Kenji Hayashida; Shigeru Kohno
Journal:  Hepatol Res       Date:  2006-02-03       Impact factor: 4.288

3.  Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines).

Authors:  Norihiro Kokudo; Kiyoshi Hasegawa; Masaaki Akahane; Hiroshi Igaki; Namiki Izumi; Takafumi Ichida; Shinji Uemoto; Shuichi Kaneko; Seiji Kawasaki; Yonson Ku; Masatoshi Kudo; Shoji Kubo; Tadatoshi Takayama; Ryosuke Tateishi; Takashi Fukuda; Osamu Matsui; Yutaka Matsuyama; Takamichi Murakami; Shigeki Arii; Masatoshi Okazaki; Masatoshi Makuuchi
Journal:  Hepatol Res       Date:  2015-01       Impact factor: 4.288

4.  No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach.

Authors:  G Torzilli; M Makuuchi; K Inoue; T Takayama; Y Sakamoto; Y Sugawara; K Kubota; A Zucchi
Journal:  Arch Surg       Date:  1999-09

Review 5.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

6.  Proposed New Sub-Grouping for Intermediate-Stage Hepatocellular Carcinoma Using Albumin-Bilirubin Grade.

Authors:  Atsushi Hiraoka; Takashi Kumada; Kazuhiro Nouso; Kunihiko Tsuji; Ei Itobayashi; Masashi Hirooka; Kazuya Kariyama; Toru Ishikawa; Toshifumi Tada; Hidenori Toyoda; Hideki Kawasaki; Yoichi Hiasa; Kojiro Michitaka
Journal:  Oncology       Date:  2016-07-01       Impact factor: 2.935

7.  One thousand fifty-six hepatectomies without mortality in 8 years.

Authors:  Hiroshi Imamura; Yasuji Seyama; Norihiro Kokudo; Atsushi Maema; Yasuhiko Sugawara; Keiji Sano; Tadatoshi Takayama; Masatoshi Makuuchi
Journal:  Arch Surg       Date:  2003-11

8.  Incorporating albumin-bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma.

Authors:  Anthony W H Chan; Charing C N Chong; Frankie K F Mo; John Wong; Winnie Yeo; Philip J Johnson; Shuangni Yu; Paul B S Lai; Anthony T C Chan; Ka-Fai To; Stephen L Chan
Journal:  J Gastroenterol Hepatol       Date:  2017-01       Impact factor: 4.029

9.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

10.  Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade.

Authors:  Hidenori Toyoda; Paul B S Lai; James O'Beirne; Charing C Chong; Sarah Berhane; Helen Reeves; Derek Manas; Richard P Fox; Winnie Yeo; Frankie Mo; Anthony W H Chan; Toshifumi Tada; Mercedes Iñarrairaegui; Arndt Vogel; Nora Schweitzer; Stephen L Chan; Bruno Sangro; Takashi Kumada; Philip J Johnson
Journal:  Br J Cancer       Date:  2016-03-29       Impact factor: 7.640
View more
  4 in total

1.  Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2021-12-08       Impact factor: 11.740

2.  Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function.

Authors:  Atsushi Hiraoka; Kojiro Michitaka; Takashi Kumada; Namiki Izumi; Masumi Kadoya; Norihiro Kokudo; Shoji Kubo; Yutaka Matsuyama; Osamu Nakashima; Michiie Sakamoto; Tadatoshi Takayama; Takashi Kokudo; Kosuke Kashiwabara; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2017-09-22       Impact factor: 11.740

3.  Whole-liver transcatheter arterial chemoinfusion and bland embolization with fine-powder cisplatin and trisacryl gelatin microspheres for treating unresectable multiple hepatocellular carcinoma.

Authors:  Akihiro Imamura; Hidetoshi Taguchi; Hideyuki Takano; Hiroyuki Funatsu; Kazuyoshi Nakamura; Hidehito Arimitsu; Satoshi Chiba
Journal:  Jpn J Radiol       Date:  2021-01-02       Impact factor: 2.374

4.  Prognostic Performance of Albumin-Bilirubin Grade With Artificial Intelligence for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib.

Authors:  Bin-Yan Zhong; Zhi-Ping Yan; Jun-Hui Sun; Lei Zhang; Zhong-Heng Hou; Min-Jie Yang; Guan-Hui Zhou; Wan-Sheng Wang; Zhi Li; Peng Huang; Shen Zhang; Xiao-Li Zhu; Cai-Fang Ni
Journal:  Front Oncol       Date:  2020-12-18       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.